Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: Growth regulation and the prospect of new cancer therapies

Journal of Cellular Biochemistry

Volumn 96, Issue 5, 2005, Pages 897-905

  Sanderson, Ralph D ^a,b   Yang, Yang ^a   Kelly, Thomas ^a   MacLeod, Veronica ^a   Dai, Yuemeng ^a   Theus, Allison ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cancer; Heparan sulfate proteoglycan (HSPG); Heparanase; Sulfatase; Tumor microenvironment

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; HEPARANASE; INTERLEUKIN 8; PROTEOHEPARAN SULFATE; SULFATASE; VASCULOTROPIN;

ANIMAL CELL; ARTICLE; CANCER THERAPY; CELL SURFACE; ENZYME BINDING; ENZYME REMODELING; ENZYME STRUCTURE; GROWTH REGULATION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PROTEOGLYCAN SYNTHESIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL MEMBRANE; CELL PROLIFERATION; EXTRACELLULAR MATRIX; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; INTERLEUKIN-8; MEMBRANE GLYCOPROTEINS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; PHENOTYPE; PROTEIN STRUCTURE, TERTIARY; PROTEOGLYCANS; SIGNAL TRANSDUCTION; SYNDECANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA;

EID: 28044442504     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20602     Document Type: Article

References (58)

1. Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U, Emerson CP, Jr. 2003. QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol 162:341-351.
2. Alexander CM, Reichsman F, Hinkes MT, Lincecum J, Becker KA, Cumberledge S, Bernfield M. 2000. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet 25:329-332.
3. Andres JL, Stanley K, Cheifetz S, Massague J. 1989. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta. J Cell Biol 109:3137-3145.
4. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E, Doglioni C. 2003. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98:474-483.
5. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS. 2001. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 14:1052-1058.
6. Beauvais DM, Burbach BJ, Rapraeger AC. 2004. The syndecan-1 ectodomain regulates {alpha}v{beta}3 integrin activity in human mammary carcinoma cells. J Cell Biol 167:171-181.
7. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. 1999. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68:729-777.
8. Bitan M, Polliack A, Zecchina G, Nagler A, Friedmann Y, Nadav L, Deutsch V, Pecker I, Eldor A, Vlodavsky I, Katz BZ. 2002. Heparanase expression in human leukemias is restricted to acute myeloid leukemias. Exp Hematol 30:34-41.
9. Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, Bicheng N, Zimmermann A, Korc M, Friess H, Buchler MW. 2000. Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 88:12-20.
10. Coussens LM, Fingleton B, Matrisian LM. 2002. Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295:2387-2392.
11. De Cat B, Muyldermans SY, Coomans C, Degeest G, Vanderschueren B, Creemers J, Biemar F, Peers B, David G. 2003. Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J Cell Biol 163:625-635.
12. Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RD. 1997. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br J Haematol 99:368-371.
13. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, Emerson CP, Jr. 2001. Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science 293:1663-1666.
14. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O, Pecker I, Vlodavsky I. 2001. Heparanase as mediator of angiogenesis: Mode of action. Faseb J 15:1661-1663.
15. Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, Sato H. 2003. Cleavage of syndecan-1 by membrane-type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 278:40764-40770.
16. Esko JD, Selleck SB. 2002. Order out of chaos: Assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 71:435-471.
17. Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC. 1993. Activating and inhibitory heparin sequences for FGF-2 (Basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem 268:23906-23914.
18. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. 1999. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 5:803-809.
19. Iozzo RV, San Antonio JD. 2001. Heparan sulfate proteoglycans: Heavy hitters in the angiogenesis arena. J Clin Invest 108:349-355.
20. Iversen PO, Sorensen DR, Benestad HB. 2002. Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias. Leukemia 16:376-381.
21. Joensuu H, Anttonen A, Eriksson M, Makitaro R, Alfthan H, Kinnula V, Leppa S. 2002. Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 62:5210-5217.
22. Kato M, Wang H, Kainulainen V, Fitzgerald ML, Ledbetter S, Ornitz DM, Bernfield M. 1998. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med 4:691-697.
23. Kelly T, Suva LJ, Huang Y, Macleod V, Mino HQ, Walker RC, Sanderson RD. 2005. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res 65:5778-5784.
24. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P, Huang Y, MacLeod V, Casciano J, Joseph L, Zhan F, Zangari M, Barlogie B, Shaughnessy J, Sanderson RD. 2003. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 63:8749-8756.
25. Kim CW, Goldberger OA, Gallo RL, Bernfield M. 1994. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol Biol Cell 5:797-805.
26. Kleeff J, Wildi S, Kumbasar A, Friess H, Lander AD, Korc M. 1999. Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells. Pancreas 19:281-288.
27. Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR, Shridhar V. 2003. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 278:23107-23117.
28. Lai JP, Chien J, Strome SE, Staub J, Montoya DP, Greene EL, Smith DI, Roberts LR, Shridhar V. 2004a. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 23:1439-1447.
29. Lai JP, Chien JR, Moser DR, Staub JK, Aderca I, Montoya DP, Matthews TA, Nagorney DM, Cunningham JM, Smith DI, Greene EL, Shridhar V, Roberts LR. 2004b. HSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 126:231-248.
30. Langford JK, Yang Y, Kieber-Emmons T, Sanderson RD. 2005. Identification of an invasion regulatory domain within the core protein of syndecan-1. J Biol Chem 280:3467-3473.
31. Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C. 2004. Prognostic value of syndecan-1 expression in breast cancer. Oncology 67:11-18.
32. Li Q, Park PW, Wilson CL, Parks WC. 2002. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111:635-646.
33. Li J, Kleeff J, Abiatari I, Kayed H, Giese NA, Felix K, Giese T, Buchler MW, Friess H. 2005. Enhanced levels of HSulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer 4:14.
34. Liu D, Shriver Z, Venkataraman G, El Shabrawi Y, Sasisekharan R. 2002. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci USA 99:568-573.
35. Marchetti D, Reiland J, Erwin B, Roy M. 2003. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int J Cancer 104:167-174.
36. Merry CL, Lyon M, Deakin JA, Hopwood JJ, Gallagher JT. 1999. Highly sensitive sequencing of the sulfated domains of heparan sulfate. J Biol Chem 274:18455-18462.
37. Miao HQ, Elkin M, Aingorn E, Ishai-Michaeli R, Stein CA, Vlodavsky I. 1999. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer 83:424-431.
38. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD. 2002. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 277:49175-49185.
39. Munshi NC, Wilson C. 2001. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 28:565-569.
40. Naggi A, Casu B, Perez M, Torri G, Cassinelli G, Penco S, Pisano C, Giannini G, Ishai-Michaeli R, Vlodavsky I. 2005. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem 280:12103-12113.
41. Ohto T, Uchida H, Yamazaki H, Keino-Masu K, Matsui A, Masu M. 2002. Identification of a novel nonlysosomal sulphatase expressed in the floor plate, choroid plexus and cartilage. Genes Cells 7:173-185.
42. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB, 1999. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res 59:3433-3441.
43. Pruneri G, Ponzoni M, Ferreri AJ, Decarli N, Tresoldi M, Raggi F, Baldessari C, Freschi M, Baldini L, Goldaniga M, Neri A, Carboni N, Bertolini F, Viale G. 2002. Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. Br J Haematol 118:817-820.
44. Roy M, Reiland J, Murry BP, Chouljenko V, Kousoulas KG, Marchetti D. 2005. Antisense-mediated suppression of Heparanase gene inhibits melanoma cell invasion. Neoplasia 7:253-262.
45. San Antonio JD, Lander AD, Karnovsky MJ, Slayter HS. 1994. Mapping the heparin-binding sites on type I collagen monomers and fibrils. J Cell Biol 125:1179-1188.
46. Sanderson RD, Yang Y, Suva LJ, Kelly T. 2004. Heparan sulfate proteoglycans and heparanase-Partners in osteolytic tumor growth and metastasis. Matrix Biol 23:341-352.
47. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A, Borset M. 2000. Serum syndecan-1: A new independent prognostic marker in multiple myeloma. Blood 95:388-392.
48. Sezer O, Niemoller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, Dietel M, Possinger K. 2000. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 79:574-577.
49. Uno F, Fujiwara T, Takata Y, Ohtani S, Katsuda K, Takaoka M, Ohkawa T, Naomoto Y, Nakajima M, Tanaka N. 2001. Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells. Cancer Res 61:7855-7860.
50. Venkataraman G, Shriver Z, Raman R, Sasisekharan R. 1999. Sequencing complex polysaccharides. Science 286:537-542.
51. Viviano BL, Paine-Saunders S, Gasiunas N, Gallagher J, Saunders S. 2004. Domain-specific modification of heparan sulfate by Qsulf1 modulates the binding of the bone morphogenetic protein antagonist Noggin. J Biol Chem 279:5604-5611.
52. Vlodavsky I, Friedmann Y. 2001. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 108:341-347.
53. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L, Pecker I. 1999. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat Med 5:793-802.
54. Wall D, Douglas S, Ferro V, Cowden W, Parish C. 2001. Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides. Thromb Res 103:325-335.
55. Wang S, Ai X, Freeman SD, Pownall ME, Lu Q, Kessler DS, Emerson CP, Jr. 2004. QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc Natl Acad Sci USA 101:4833-4838.
56. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. 1996. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 271:10079-10086.
57. Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J, Sanderson RD. 2002. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100:610-617.
58. Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, Kussie P, Yaccoby S, Epstein J, Suva LJ, Kelly T, Sanderson RD. 2005. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 105:1303-1309.